The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Zai Lab announces approval of Zejula in relapsed ovarian cancer in Hong Kong

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Zai Lab Limited, a Shanghai-based biopharmaceutical company, announced the Hong Kong Department of Health has approved Zejula (niraparib), an oral, once-daily poly polymerase inhibitor in Hong Kong for adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian cancer who are in a complete response or partial response to platinum-based chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account